These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38586420)
1. A novel tumor mutation-related long non-coding RNA signature for predicting overall survival and immunotherapy response in lung adenocarcinoma. Chen W; Liao C; Xiang X; Li H; Wu Q; Li W; Ma Q; Chen N; Chen B; Li G Heliyon; 2024 Apr; 10(7):e28670. PubMed ID: 38586420 [TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma. Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J Front Genet; 2022; 13():838624. PubMed ID: 35928454 [TBL] [Abstract][Full Text] [Related]
3. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M Front Genet; 2022; 13():951311. PubMed ID: 36406130 [No Abstract] [Full Text] [Related]
4. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma. Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578 [TBL] [Abstract][Full Text] [Related]
5. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma. Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612 [TBL] [Abstract][Full Text] [Related]
6. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma. Ma C; Li F; Gu Z; Yang Y; Qi Y Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938 [No Abstract] [Full Text] [Related]
7. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients. Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B Front Genet; 2022; 13():966896. PubMed ID: 36186456 [No Abstract] [Full Text] [Related]
8. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma. Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S Front Genet; 2022; 13():862741. PubMed ID: 35368663 [No Abstract] [Full Text] [Related]
9. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response. Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328 [TBL] [Abstract][Full Text] [Related]
10. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma. Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203 [TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. Wang F; Lin H; Su Q; Li C World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740 [TBL] [Abstract][Full Text] [Related]
12. Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma. Zhao J; Li G; Zhao G; Wang W; Shen Z; Yang Y; Huang Y; Ye L Front Oncol; 2022; 12():986367. PubMed ID: 36387240 [TBL] [Abstract][Full Text] [Related]
13. Identification of the Prognostic Significance of Somatic Mutation-Derived LncRNA Signatures of Genomic Instability in Lung Adenocarcinoma. Geng W; Lv Z; Fan J; Xu J; Mao K; Yin Z; Qing W; Jin Y Front Cell Dev Biol; 2021; 9():657667. PubMed ID: 33855028 [No Abstract] [Full Text] [Related]
14. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma. Hu J; Wang T; Chen Q Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848 [TBL] [Abstract][Full Text] [Related]
15. A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study. Dong J; Tao T; Yu J; Shan H; Liu Z; Zheng G; Li Z; Situ W; Zhu X; Li Z Cancer Rep (Hoboken); 2024 Jan; 7(1):e1925. PubMed ID: 38043920 [TBL] [Abstract][Full Text] [Related]
16. Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma. Zeng Z; Liang Y; Shi J; Xiao L; Tang L; Guo Y; Chen F; Lin G Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36428951 [TBL] [Abstract][Full Text] [Related]
17. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z Front Immunol; 2022; 13():951455. PubMed ID: 36189298 [TBL] [Abstract][Full Text] [Related]
18. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma. Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642 [TBL] [Abstract][Full Text] [Related]
19. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. Zhou L; Fang H; Guo F; Yin M; Long H; Weng G J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868 [TBL] [Abstract][Full Text] [Related]
20. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma. You J; Fang W; Zhao Q; Chen L; Chen L; Chen F Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]